- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 265/28 - Oxazines-1, 4Oxazines-1, 4 hydrogénées
Détention brevets de la classe C07D 265/28
Brevets de cette classe: 66
Historique des publications depuis 10 ans
|
2
|
4
|
7
|
2
|
3
|
10
|
2
|
4
|
2
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 674 |
4 |
| Bristol-myers Squibb Company | 4865 |
2 |
| Amgen Inc. | 3902 |
2 |
| Ricoh Company, Ltd. | 13222 |
2 |
| Adverio Pharma GmbH | 44 |
2 |
| BioCryst Pharmaceuticals, Inc. | 176 |
2 |
| Oregon Health & Science University | 758 |
2 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 806 |
2 |
| Kemimedi Co.Ltd | 3 |
2 |
| Cullgen (Shanghai), Inc. | 32 |
2 |
| Vigil Neuroscience, Inc. | 42 |
2 |
| Merck Sharp & Dohme LLC | 3752 |
2 |
| Glaxosmithkline LLC | 539 |
1 |
| Hoffmann-La Roche Inc. | 3277 |
1 |
| Baker Hughes Incorporated | 5500 |
1 |
| 3m Innovative Properties Company | 17969 |
1 |
| BASF SE | 20421 |
1 |
| The Regents of the University of California | 19544 |
1 |
| International Business Machines Corporation | 60178 |
1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 93 |
1 |
| Autres propriétaires | 32 |